Back to Search Start Over

Complete tumor necrosis after neoadjuvant chemotherapy defines good responders in patients with Ewing sarcoma

Authors :
Santiago A. Lozano‐Calderón
Jose Ignacio Albergo
Olivier Q. Groot
Nelson A. Merchan
Jad M. El Abiad
Vanessa Salinas
Luis Carlos Gomez Mier
Camilo Soto Montoya
Marco L. Ferrone
John E. Ready
Francisco J. Linares
Adam S. Levin
Manuel Peleteiro Pensado
José Juan Pozo Kreilinger
Irene Barrientos Ruiz
Eduardo J. Ortiz‐Cruz
Mark C. Gebhardt
Gregory M. Cote
Edwin Choy
Dimitrios Spentzos
Yin P. Hung
Vikram Deshpande
Ivan A. Chebib
Robert Allan McCulloch
Germán Farfalli
Luis Aponte Tinao
Carol D. Morris
Gunnlaugur Petur Nielsen
Megan E. Anderson
Lee M. Jeys
Source :
Cancer. 129:60-70
Publication Year :
2022
Publisher :
Wiley, 2022.

Abstract

Survival in patients who have Ewing sarcoma is correlated with postchemotherapy response (tumor necrosis). This treatment response has been categorized as the response rate, similar to what has been used in osteosarcoma. There is controversy regarding whether this is appropriate or whether it should be a dichotomy of complete versus incomplete response, given how important a complete response is for in overall survival of patients with Ewing sarcoma. The purpose of this study was to evaluate the impact that the amount of chemotherapy-induced necrosis has on (1) overall survival, (2) local recurrence-free survival, (3) metastasis-free survival, and (4) event-free survival in patients with Ewing sarcoma.In total, 427 patients who had Ewing sarcoma or tumors in the Ewing sarcoma family and received treatment with preoperative chemotherapy and surgery at 10 international institutions were included. Multivariate Cox proportional-hazards analyses were used to assess the associations between tumor necrosis and all four outcomes while controlling for clinical factors identified in bivariate analysis, including age, tumor volume, location, surgical margins, metastatic disease at presentation, and preoperative radiotherapy.Patients who had a complete (100%) tumor response to chemotherapy had increased overall survival (hazard ratio [HR], 0.26; 95% CI, 0.14-0.48; p .01), recurrence-free survival (HR, 0.40; 95% CI, 0.20-0.82; p = .01), metastasis-free survival (HR, 0.27; 95% CI, 0.15-0.46; p ≤ .01), and event-free survival (HR, 0.26; 95% CI, 0.16-0.41; p ≤ .01) compared with patients who had a partial (0%-99%) response.Complete tumor necrosis should be the index parameter to grade response to treatment as satisfactory in patients with Ewing sarcoma. Any viable tumor in these patients after neoadjuvant treatment should be of oncologic concern. These findings can affect the design of new clinical trials and the risk-stratified application of conventional or novel treatments.

Subjects

Subjects :
Cancer Research
Oncology

Details

ISSN :
10970142 and 0008543X
Volume :
129
Database :
OpenAIRE
Journal :
Cancer
Accession number :
edsair.doi.dedup.....f839655f59b711991f33eb2f1e78ff82
Full Text :
https://doi.org/10.1002/cncr.34506